Secondary pulmonary arterial hypertension: Treated with endothelin receptor blockade

Texas Heart Institute Journal

Volumn 32, Issue 3, 2005, Pages 405-410

  Sharma, Sat ^a,b   Kashour, Tarek ^a   Philipp, Roger ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Bosentan; Calcium channel blockers administration dosage; Endothelin 1 antagonists and inhibitors; Epoprostenol therapeutic use; Hypertension, pulmonary drug therapy; Liver drug effects

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DISEASE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; GRANULOMATOUS VASCULITIS; HEART ATRIUM SEPTUM DEFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ARTERY PRESSURE; MALE; MITRAL VALVE STENOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SCLERODERMA; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; RECEPTORS, ENDOTHELIN; SARCOIDOSIS, PULMONARY; SCLERODERMA, SYSTEMIC; SULFONAMIDES; THROMBOEMBOLISM;

EID: 24944538071     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sharma S. Treatment of pulmonary arterial hypertension: a step forward. Chest 2003;124:8-11.
2. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
3. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342: 1866-70.
4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-23.
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
6. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124: 247-54.
7. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2:123-37.
8. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50.
9. Kato H, Katori T, Nakamura Y, Kawarasaki H. Moderate-term effect of epoprostenol on severe portopulmonary hypertension. Pediatr Cardiol 2003;24:50-3.
10. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130:740-3.
11. Fishman AP. Primary pulmonary hypertension: a look back. J Am Coll Cardiol 2004;43:2S-4S.
12. Rich S, Kaufmann E, Levy PS. The effects of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
13. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
14. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):62S-67S.
15. Palevsky HI, Fishman AP. Chronic cor pulmonale. Etiology and management. JAMA 1990;263:2347-53.
16. Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 1984;4:890-901.
17. Melot C, Hallemans R, Naeije R, Mois P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984;130:612-6.
18. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
19. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994;266(5 Pt 1):L536-43.
20. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
21. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78: 1207-13.
22. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double blind, crossover study. J Am Coll Cardiol 2004;43:1149-53.
23. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
24. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43(12 Suppl S):48S-55S.